{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:19:11Z","timestamp":1791609551777,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die Alzheimer-Krankheit ist eine der gro\u00dfen Volkskrankheiten mit bisher allein symptomatischen Therapieoptionen. Neue Erkenntnisse zu einem Krankheitskontinuum mit einer sehr langen pr\u00e4klinischen und fr\u00fchsymptomatischen Krankheitsphase sowie molekulare Therapiestrategien, die auf den Erkenntnissen zur molekularen Neurobiologie der Erkrankung fu\u00dfen, er\u00f6ffnen eine Vielzahl neuer therapeutischer Strategien. Im Jahr 2021 ist erstmals ein Antiamyloidantik\u00f6rper in den USA als krankheitsmodifizierende Therapie bei Alzheimer-Krankheit zugelassen worden, was einen ersten, sehr kontrovers diskutierten Schritt hin zu einer molekularen, ursachenorientierten Therapie darstellt. Die \u00dcbersicht stellt die am weitesten entwickelten molekularen Therapiestrategien sowie die Auswirkungen der zugelassenen Antik\u00f6rpertherapie f\u00fcr die Praxis vor. Die Besonderheiten einer Langzeittherapie mit i.v. Infusionen in einer besonders vulnerablen Patientenpopulation und einem speziellen Nebenwirkungsprofil wird f\u00fcr die Implementierung in die Praxis gro\u00dfe Herausforderungen mit sich bringen und ein hohes Ma\u00df an Kooperation erfordern. Die Zukunft der Alzheimer-Therapie mit einem multimodalen Therapieansatz mit verschiedenen Substanzen wird diesen Trend wahrscheinlich noch verst\u00e4rken.<\/jats:p>","DOI":"10.1007\/s00115-021-01222-w","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T11:02:52Z","timestamp":1636023772000},"page":"1239-1248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Krankheitsmodifizierende Therapieans\u00e4tze bei Alzheimer-Krankheit","Disease-modifying treatment approaches for Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"92","author":[{"given":"Lutz","family":"Fr\u00f6lich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Hausner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"issue":"3","key":"1222_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):270\u2013279","journal-title":"Alzheimers Dement"},{"issue":"17","key":"1222_CR2","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1001\/jama.2021.3854","volume":"325","author":"GC Alexander","year":"2021","unstructured":"Alexander\u00a0GC, Emerson\u00a0S, Kesselheim\u00a0AS (2021) Evaluation of aducanumab for alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA 325(17):1717\u20131718","journal-title":"JAMA"},{"issue":"Pt 3","key":"1222_CR3","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","volume":"126","author":"T Arendt","year":"2016","unstructured":"Arendt\u00a0T, Stieler\u00a0JT, Holzer\u00a0M (2016) Tau and tauopathies. Brain Res Bull 126(Pt 3):238\u2013292","journal-title":"Brain Res Bull"},{"issue":"4","key":"1222_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00115-012-3688-1","volume":"84","author":"H Braak","year":"2013","unstructured":"Braak\u00a0H, Feldengut\u00a0S, Del Tredici\u00a0K (2013) Pathogenese und Pr\u00e4vention des M. Alzheimer: Wann und auf welche Weise beginnt der pathologische Prozess? Nervenarzt 84(4):477\u2013482","journal-title":"Nervenarzt"},{"issue":"9","key":"1222_CR5","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00115-019-0778-3","volume":"90","author":"S Castro-Gomez","year":"2019","unstructured":"Castro-Gomez\u00a0S, Binder\u00a0J, Heneka\u00a0MT (2019) Neuroinflammation als Motor der Alzheimer-Erkrankung. Nervenarzt 90(9):898\u2013906","journal-title":"Nervenarzt"},{"key":"1222_CR6","doi-asserted-by":"publisher","first-page":"S567","DOI":"10.3233\/JAD-179941","volume":"64","author":"NE Clein","year":"2018","unstructured":"Clein\u00a0NE, Bicca\u00a0MA, Viola\u00a0KL, Klein\u00a0WL (2018) The amyloid-oligomer hypothesis: beginning of the third decade. J\u00a0Alzheimer Dis 64:S567\u2013S610","journal-title":"J Alzheimer Dis"},{"issue":"4","key":"1222_CR7","first-page":"398","volume":"8","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Apostolova LG et al (2021) Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis.8(4):398\u2013410","journal-title":"J Prev Alzheimers Dis"},{"key":"1222_CR8","doi-asserted-by":"crossref","first-page":"e12179","DOI":"10.1002\/trc2.12179","volume":"7","author":"J Cummings","year":"2021","unstructured":"Cummings\u00a0J, Lee\u00a0G, Zhong\u00a0K et\u00a0al (2021) Alzheimer\u2019s disease drug development pipeline: 2021. Alzheimers Dement 7:e12179","journal-title":"Alzheimers Dement"},{"issue":"10","key":"1222_CR9","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","volume":"181","author":"B Dunn","year":"2021","unstructured":"Dunn B, Stein P, Cavazzoni P (2021) Approval of aducanumab for alzheimer disease\u2014the FDA\u2019s perspective. JAMA Intern Med. 181(10):1276\u20131278","journal-title":"JAMA Intern Med."},{"issue":"9","key":"1222_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00115-019-0758-7","volume":"90","author":"K Flie\u00dfbach","year":"2019","unstructured":"Flie\u00dfbach\u00a0K, McCormick\u00a0C, Kaulen\u00a0B, Schneider\u00a0A (2019) Anti-Tau-Therapien \u2013 was k\u00f6nnen wir erwarten? Nervenarzt 90(9):891\u2013897","journal-title":"Nervenarzt"},{"issue":"10","key":"1222_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamainternmed.2021.4604","volume":"181","author":"B Gyawali","year":"2021","unstructured":"Gyawali B, Ross JS, Kesselheim AS (2021) Fulfilling the mandate of the US food and drug administration\u2019s accelerated approval pathway: the need for reforms. JAMA Intern Med:181(10):1275\u20131276","journal-title":"JAMA Intern Med"},{"issue":"9","key":"1222_CR12","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s00115-019-0751-1","volume":"90","author":"C Haass","year":"2019","unstructured":"Haass\u00a0C, Levin\u00a0J (2019) Hat die Alzheimer-Forschung versagt? Das Scheitern amyloid-basierter klinischer Studien. Nervenarzt 90(9):884\u2013890","journal-title":"Nervenarzt"},{"issue":"4","key":"1222_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig\u00a0LS, Vellas\u00a0B, Woodward\u00a0M et\u00a0al (2018) Trial of solanezumab for mild dementia due to alzheimer\u2019s disease. N\u00a0Engl J Med 378(4):321\u2013330","journal-title":"N Engl J Med"},{"key":"1222_CR14","unstructured":"https:\/\/www.deutsche-alzheimer.de\/fileadmin\/alz\/pdf\/factsheets\/infoblatt1_haeufigkeit_demenzerkrankungen_dalzg.pdf. Zugegriffen: 29. Juli 2021"},{"issue":"10","key":"1222_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Y Hou","year":"2019","unstructured":"Hou\u00a0Y, Dan\u00a0X, Babbar\u00a0M, Wei\u00a0Y et\u00a0al (2019) Ageing as a\u00a0risk factor for neurodegenerative disease. Nat Rev Neurol 15(10):565\u2013581","journal-title":"Nat Rev Neurol"},{"key":"1222_CR16","unstructured":"International Alzheimer\u2019s and Related Dementia Research Portfolio https:\/\/iadrp.nia.nih.gov\/about\/cadro. Zugegriffen: 29. Juli 2021"},{"key":"1222_CR17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack\u00a0CR Jr, Bennett\u00a0DA, Blennow\u00a0K et al (2018) NIA-AA research framework: toward a\u00a0biological definition of alzheimer\u2019s disease. Alzheimers Dement 14:535\u2013562","journal-title":"Alzheimers Dement"},{"issue":"10","key":"1222_CR18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-021-01546-6","volume":"81","author":"C Ji","year":"2021","unstructured":"Ji\u00a0C, Sigurdsson\u00a0EM (2021) Current status of clinical trials on tau immunotherapies. Drugs 81(10):1135\u20131152","journal-title":"Drugs"},{"key":"1222_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T J\u00f6nsson","year":"2012","unstructured":"J\u00f6nsson\u00a0T, Atwal\u00a0JK, Steinberg\u00a0S et al (2012) A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature 488:96\u201399","journal-title":"Nature"},{"issue":"3","key":"1222_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):263\u2013269","journal-title":"Alzheimers Dement"},{"key":"1222_CR21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun\u00a0MA, Lo\u00a0AC, Duggan Evans\u00a0C et\u00a0al (2021) Donanemab in early Alzheimer\u2019s disease. N\u00a0Engl J Med 384:1691\u20131704","journal-title":"N Engl J Med"},{"key":"1222_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","volume":"1","author":"P Novak","year":"2021","unstructured":"Novak\u00a0P, Kovacech\u00a0B, Katina\u00a0S et al (2021) ADAMANT: a\u00a0placebo-controlled randomized phase 2\u00a0study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease. Nat Aging 1:521\u2013534","journal-title":"Nat Aging"},{"issue":"1","key":"1222_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki\u00a0S, Lasser\u00a0RA, Dorflinger\u00a0E et\u00a0al (2017) A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther 9(1):95","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1222_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrneurol.2017.162","volume":"14","author":"JC Polanco","year":"2018","unstructured":"Polanco\u00a0JC, Li\u00a0C, Bodea\u00a0LG et al (2018) Amyloid\u2011\u03b2 and tau complexity\u2014towards improved biomarkers and targeted therapies. Nat Rev Neurol 14(1):22\u201339","journal-title":"Nat Rev Neurol"},{"issue":"10284","key":"1222_CR25","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens\u00a0P, De Strooper\u00a0B, Kivipelto\u00a0M et\u00a0al (2021) Alzheimer\u2019s disease. Lancet 397(10284):1577\u20131590","journal-title":"Lancet"},{"issue":"5","key":"1222_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1001\/jama.2021.11768","volume":"326","author":"KA Schulman","year":"2021","unstructured":"Schulman\u00a0KA, Greicius\u00a0MD, Richman\u00a0B (2021) Will CMS find aducanumab reasonable and necessary for alzheimer disease after FDA approval? JAMA 326(5):383\u2013384","journal-title":"JAMA"},{"issue":"6","key":"1222_CR27","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/YCO.0b013e328358e4f2","volume":"25","author":"S Schwarz","year":"2012","unstructured":"Schwarz\u00a0S, Fr\u00f6lich\u00a0L, Burns\u00a0A (2012) Pharmacological treatment of dementia. Curr Opin Psychiatry 25(6):542\u2013550","journal-title":"Curr Opin Psychiatry"},{"key":"1222_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe\u00a0DJ, Hardy\u00a0J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25\u00a0years. EMBO Mol Med 8:595\u2013608","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1222_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson\u00a0CJ, Zhang\u00a0Y, Dhadda\u00a0S et al (2021) A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther 13(1):80","journal-title":"Alzheimers Res Ther"},{"key":"1222_CR30","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","volume":"15","author":"L Vermunt","year":"2019","unstructured":"Vermunt\u00a0L, Sikkes\u00a0SAM, van den Hout\u00a0A et\u00a0al (2019) Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype. Alzheimers Dement 15:888\u2013898","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1222_CR31","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00115-019-0772-9","volume":"90","author":"J Vogelgsang","year":"2019","unstructured":"Vogelgsang\u00a0J, Wiltfang\u00a0J (2019) Neue Biomarker f\u00fcr die Alzheimer-Krankheit in Liquor und Blut [New biomarkers for Alzheimer\u2019s disease in cerebrospinal fluid and blood]. Nervenarzt 90(9):907\u2013913","journal-title":"Nervenarzt"},{"key":"1222_CR32","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","volume":"29","author":"X Wang","year":"2019","unstructured":"Wang\u00a0X, Sun\u00a0G, Feng\u00a0T et al (2019) Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression. Cell Res 29:787\u2013803","journal-title":"Cell Res"},{"issue":"1","key":"1222_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-170560","volume":"61","author":"GK Wilcock","year":"2017","unstructured":"Wilcock\u00a0GK, Gauthier\u00a0S, Frisoni\u00a0GB et al (2017) Potential of low dose leuco-methylthioninium Bis(Hydromethanesulphonate) (LMTM) monotherapy for treatment of mild alzheimer\u2019s disease: cohort analysis as modified primary outcome in a\u00a0phase III clinical trial. J Alzheimers Dis 61(1):435\u2013457","journal-title":"J. Alzheimers Dis."}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-021-01222-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T03:05:36Z","timestamp":1699758336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-021-01222-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1222"],"URL":"https:\/\/doi.org\/10.1007\/s00115-021-01222-w","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"12 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00115-022-01366-3","URL":"https:\/\/doi.org\/10.1007\/s00115-022-01366-3","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Fr\u00f6lich und L.\u00a0Hausner geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}